Phynova presents data relating to PYN6

    
  Phynova Group PLC
  30 May 2008
   

    30 May 2008

    Phynova Group PLC

    ("Phynova" or the "Company")


    PHYNOVA PRESENTS DATA RELATING TO PYN6 ACTIVITY AGAINST MRSA AT AMERICAN SOCIETY FOR MICROBIOLOGY


    Phynova (AIM: PYN), the developer of prescription pharmaceuticals derived from plants used in Chinese medicines, will present a poster
detailing results from laboratory studies using its drug candidate, PYN6, a novel treatment for MRSA, at the 108th annual general meeting of
the American Society for Microbiology (ASM) between 1 - 5 June at the Boston Convention and Exhibition Centre. The conference is a leading
showcase of life sciences research.

    The poster details how an improved extraction technique yields greater activity against MRSA than previous extracts that used the
solvent hexane.

    Phynova's poster: Abstract A-008: Antibacterial Activity of a Novel Extract from Salvia miltiorrhiza (PYN6) against MRSA (Poster
presented by Dr RR Cutler, Medicines Research Group, University of East London, UK and Dr T Mills, Phynova on Monday June 2 2008, 1pm,
Poster Hall).

    -ENDS-


    For further information, please contact: 

 Phynova Group PLC   Tel: [phone]
 Tony Mills

 Capital MS&L       Tel: [phone]
 Mary Clark/Penny
 Freer



     Notes to editors:

    About Phynova
    Phynova is a UK incorporated company developing prescription pharmaceuticals derived from plants used in Chinese medicines. PYN6 is a
fraction isolated from a single plant that has been found in pre-clinical screening assays conducted both in China and in the UK to have
activity against clinical isolates of MRSA and against the bacterium associated with the development of acne, Propionobacterium acnes.
Initial research by the University of East London shows that PYN6 is active against MRSA at one tenth the concentration of the commonly used
topical antibiotic, mupirocin. In laboratory studies extending over three weeks of MRSA strain culture with PYN6, none of the MRSA strains
tested could be converted to PYN6 resistance.  Phynova is now planning formulation studies to assess the potential of PYN6 for topical
application in both MRSA and acne. 

    Phynova´s lead product for hepatitis C has now completed a Phase I/II trial in the US and the Phase IIb trial is scheduled to commence
in the first half of 2008. Two further products, for fatty liver disease and post-operative ileus, are targeted for entry to the clinic
during 2008. 
    
For further information please visit www.phynova.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NRABBLFXVEBZBBL